» Articles » PMID: 22247016

The Natural History of Macroprolactinaemia

Overview
Specialty Endocrinology
Date 2012 Jan 17
PMID 22247016
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Macroprolactinaemia is a condition in which serum prolactin (PRL) consists mainly of large molecular weight PRL (macroPRL). The aim of this study was to examine the natural history of macroprolactinaemia.

Design And Participants: Six hundred and fifty-four hospital workers participated in this study, including 27 subjects with macroprolactinaemia and 627 controls. MacroPRL and serum PRL concentrations were evaluated over a 4-year period. The ratio of macroPRL was examined by the polyethylene glycol (PEG) method and gel filtration chromatography. IgG-bound PRL and anti-PRL autoantibodies were examined by protein G and (125)I-PRL binding studies respectively.

Results: Over the 4 years of the study, all 27 macroprolactinaemic subjects had persistent macroprolactinaemia without the development of raised free PRL, while none of the 627 controls developed macroprolactinaemia. The ratios of PEG-precipitable PRL and IgG-bound PRL did not significantly change, but (125)I-PRL binding ratios significantly increased. As a whole, total and free serum PRL concentrations did not significantly change in subjects with macroprolactinaemia over the 4-year period. However, hyperprolactinaemia developed in five of the 18 macroprolactinaemic subjects who were initially normoprolactinaemic along with an increase in anti-PRL autoantibody titres. One of the remaining nine macroprolactinaemic subjects who were initially hyperprolactinaemic showed a decrease in serum PRL concentrations, which occurred concomitantly with a decrease in the anti-PRL autoantibody titre.

Conclusions: Macroprolactinaemia may develop before middle age and is likely a chronic condition leading to hyperprolactinaemia.

Citing Articles

Macroprolactinemia: a mini-review and update on clinical practice.

Koniares K, Benadiva C, Engmann L, Nulsen J, Grow D F S Rep. 2023; 4(3):245-250.

PMID: 37719092 PMC: 10504566. DOI: 10.1016/j.xfre.2023.05.005.


Evaluation of autoantibodies and immunoglobulin G subclasses in women with suspected macroprolactinemia.

Yu C, Fan F, Hu S, Meng L, Xu D, Wang J J Clin Lab Anal. 2020; 34(11):e23456.

PMID: 32597541 PMC: 7676205. DOI: 10.1002/jcla.23456.


High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?.

Espinosa-Cardenas E, Sanchez-Garcia M, Ramirez-Renteria C, Mendoza-Zubieta V, Sosa-Eroza E, Mercado M Endocrine. 2020; 70(1):143-149.

PMID: 32548734 DOI: 10.1007/s12020-020-02388-0.


Optimizing laboratory defined macroprolactin algorithm.

Sostaric M, Bokulic A, Marijancevic D, Zec I Biochem Med (Zagreb). 2019; 29(2):020706.

PMID: 31223260 PMC: 6559613. DOI: 10.11613/BM.2019.020706.


Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism.

Vilar L, Abucham J, Albuquerque J, Araujo L, Azevedo M, Boguszewski C Arch Endocrinol Metab. 2018; 62(2):236-263.

PMID: 29768629 PMC: 10118988. DOI: 10.20945/2359-3997000000032.